NASDAQ:DXCM - DexCom Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $461.19
Forecasted Upside: 6.83 %
Number of Analysts: 16
Breakdown:
0 Sell Ratings
2 Hold Ratings
14 Buy Ratings
0 Strong Buy Ratings

^$431.72 As of 06/23/2021 01:00 AM ET

▲ +4.21 (0.98%)

1 month | 3 months | 12 months

Get New DexCom Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DXCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXCM

^$461.19

▲ +6.83% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for DexCom in the last 3 months. The average price target is $461.19, with a high forecast of $500.00 and a low forecast of $380.00. The average price target represents a 6.83% upside from the last price of $431.72.

Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in DexCom. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
12 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/31/2019

0 strong buy ratings
15 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/30/2020

0 strong buy ratings
17 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/28/2020

0 strong buy ratings
16 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/26/2020

0 strong buy ratings
14 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/25/2020

0 strong buy ratings
13 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/25/2021

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/24/2021

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/28/2021	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$380.00	High
5/24/2021	Barclays	Initiated Coverage	Overweight	$500.00	Medium
4/30/2021	Citigroup	Boost Price Target		$480.00 ➝ $488.00	High
4/30/2021	Canaccord Genuity	Boost Price Target	Buy	$445.00 ➝ $455.00	High
4/30/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target	Buy	$480.00 ➝ $488.00	High
4/30/2021	Raymond James	Boost Price Target	Outperform	$449.00 ➝ $466.00	High
4/15/2021	Atlantic Securities	Initiated Coverage	Overweight	$438.00	Medium
2/12/2021	Citigroup	Lower Price Target	Buy	$485.00 ➝ $480.00	Low
2/12/2021	Oppenheimer	Boost Price Target	Outperform	$415.00 ➝ $449.00	Low
2/12/2021	Morgan Stanley	Boost Price Target	Equal Weight	$402.00 ➝ $410.00	Low
2/12/2021	Raymond James	Boost Price Target	Outperform	$415.00 ➝ $449.00	Low
1/29/2021	Piper Sandler	Boost Price Target	Overweight	$465.00 ➝ $500.00	High
1/6/2021	UBS Group	Upgrade	Neutral ➝ Buy	$410.00 ➝ $445.00	N/A
12/15/2020	Morgan Stanley	Boost Price Target	Equal Weight	$398.00 ➝ $402.00	Low
12/10/2020	Canaccord Genuity	Lower Price Target	Buy	$475.00 ➝ $435.00	High
12/10/2020	Raymond James	Reiterated Rating	Buy		High
11/20/2020	Piper Sandler	Reiterated Rating	Buy	$465.00	Medium
10/28/2020	Stifel Nicolaus	Lower Price Target	Buy	$500.00 ➝ $475.00	High
10/28/2020	Canaccord Genuity	Lower Price Target	Buy	$500.00 ➝ $475.00	High
10/28/2020	Raymond James	Lower Price Target	Outperform	$450.00 ➝ $438.00	High
10/28/2020	Morgan Stanley	Lower Price Target	Equal Weight	$428.00 ➝ $398.00	High
10/2/2020	Wells Fargo & Company	Downgrade	Equal Weight ➝ Underweight	$420.00 ➝ $350.00	High
7/29/2020	UBS Group	Boost Price Target	Neutral	$335.00 ➝ $400.00	High
7/29/2020	Morgan Stanley	Boost Price Target	Equal Weight	$377.00 ➝ $428.00	Low
7/29/2020	Canaccord Genuity	Boost Price Target	Buy	$435.00 ➝ $500.00	Medium
7/29/2020	Raymond James	Boost Price Target	Outperform	$395.00 ➝ $450.00	Low
7/29/2020	Stifel Nicolaus	Boost Price Target	Buy	$385.00 ➝ $500.00	Low
7/29/2020	SVB Leerink	Boost Price Target	Equal Weight ➝ Outperform	$465.00 ➝ $485.00	Medium
7/29/2020	Citigroup	Boost Price Target	Buy	$440.00 ➝ $485.00	Medium
7/29/2020	Piper Sandler	Boost Price Target	Overweight	$450.00 ➝ $465.00	Medium
7/28/2020	Oppenheimer	Initiated Coverage	Buy	$360.00 ➝ $445.00	High
7/28/2020	Bank of America	Reiterated Rating	Buy	$500.00	High
7/27/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$360.00 ➝ $450.00	Medium
7/7/2020	Cowen	Boost Price Target	Positive ➝ Outperform	$430.00 ➝ $450.00	Low
6/17/2020	Bank of America	Boost Price Target	Buy	$375.00 ➝ $500.00	Low
6/9/2020	Raymond James	Boost Price Target	Outperform	$360.00 ➝ $395.00	High
6/3/2020	Citigroup	Boost Price Target	Average ➝ Buy	$361.00 ➝ $440.00	Medium
5/27/2020	Piper Sandler	Boost Price Target	Overweight	$375.00 ➝ $450.00	High
5/14/2020	Wells Fargo & Company	Initiated Coverage	Equal Weight	$420.00	Low
4/30/2020	UBS Group	Boost Price Target	Neutral	$275.00 ➝ $335.00	Medium
4/29/2020	Guggenheim	Boost Price Target	Buy	$385.00 ➝ $395.00	High
4/29/2020	Citigroup	Boost Price Target	Buy	$330.00 ➝ $361.00	High
4/29/2020	Morgan Stanley	Boost Price Target	Equal Weight	$278.00 ➝ $377.00	Medium
4/29/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$300.00 ➝ $360.00	Medium
4/29/2020	Stifel Nicolaus	Boost Price Target	Buy	$270.00 ➝ $385.00	Medium
4/29/2020	Oppenheimer	Boost Price Target	Outperform	$305.00 ➝ $360.00	High
4/29/2020	Cowen	Boost Price Target	Outperform	$300.00 ➝ $360.00	High
4/29/2020	Robert W. Baird	Boost Price Target	Outperform	$296.00 ➝ $373.00	High
4/29/2020	Piper Sandler	Boost Price Target	Overweight	$300.00 ➝ $375.00	High
4/29/2020	BTIG Research	Reiterated Rating	Hold		High
4/27/2020	Raymond James	Boost Price Target	Outperform	$288.00 ➝ $350.00	Low
4/24/2020	SVB Leerink	Boost Price Target	Outperform	$316.00 ➝ $385.00	Medium
3/27/2020	Morgan Stanley	Boost Price Target	Equal Weight	$270.00 ➝ $278.00	High
3/23/2020	Stephens	Lower Price Target	Overweight	$300.00 ➝ $240.00	Low
3/6/2020	Oppenheimer	Boost Price Target	Outperform	$285.00 ➝ $305.00	Low
3/4/2020	Citigroup	Initiated Coverage	Buy	$330.00 ➝ $330.00	Low
2/18/2020	Morgan Stanley	Boost Price Target	Equal Weight	$225.00 ➝ $270.00	High
2/14/2020	Piper Sandler	Boost Price Target		$230.00 ➝ $300.00	Low
2/14/2020	Cfra	Boost Price Target	Hold	$205.00 ➝ $258.00	High
2/14/2020	Oppenheimer	Boost Price Target	Outperform	$250.00 ➝ $285.00	High
2/14/2020	Cowen	Reiterated Rating	Outperform	$250.00 ➝ $300.00	High
2/14/2020	Guggenheim	Reiterated Rating	Buy	$245.00 ➝ $300.00	High
2/14/2020	Canaccord Genuity	Boost Price Target	Buy	$255.00 ➝ $300.00	High
2/14/2020	Stephens	Boost Price Target	Overweight	$255.00 ➝ $300.00	High
2/14/2020	UBS Group	Boost Price Target	Neutral	$250.00 ➝ $275.00	High
2/14/2020	Raymond James	Boost Price Target	Outperform	$258.00 ➝ $288.00	High
2/14/2020	Stifel Nicolaus	Boost Price Target	Buy	$250.00 ➝ $300.00	High
1/7/2020	Cowen	Reiterated Rating	Buy	$250.00	High
12/20/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$215.00 ➝ $255.00	Low
12/18/2019	Bank of America	Reiterated Rating	Buy	$220.00 ➝ $250.00	Low
12/17/2019	Morgan Stanley	Boost Price Target	Equal Weight	$202.00 ➝ $225.00	Medium
12/16/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$230.00	Medium
11/18/2019	Piper Jaffray Companies	Reiterated Rating	Overweight		High
11/7/2019	Oppenheimer	Boost Price Target		$180.00 ➝ $205.00	Medium
11/7/2019	Canaccord Genuity	Boost Price Target	Buy	$185.00 ➝ $195.00	High
11/7/2019	Raymond James	Boost Price Target	Outperform	$172.00 ➝ $189.00	High
11/7/2019	Robert W. Baird	Boost Price Target	Outperform	$195.00 ➝ $240.00	High
11/7/2019	Jefferies Financial Group	Boost Price Target	Buy	$180.00 ➝ $200.00	High
11/7/2019	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$190.00 ➝ $215.00	High
11/7/2019	Guggenheim	Upgrade	Neutral ➝ Buy		High
10/22/2019	Stifel Nicolaus	Initiated Coverage	Buy	$190.00	High
9/23/2019	Piper Jaffray Companies	Set Price Target	Buy	$182.00	Medium
9/3/2019	BMO Capital Markets	Boost Price Target	Outperform	$180.00 ➝ $190.00	Low
8/29/2019	Robert W. Baird	Boost Price Target	Outperform	$186.00 ➝ $195.00	Low
8/1/2019	Oppenheimer	Boost Price Target		$167.00 ➝ $180.00	Medium
8/1/2019	Bank of America	Boost Price Target	Buy	$162.00 ➝ $185.00	Medium
8/1/2019	Robert W. Baird	Boost Price Target	Outperform	$180.00 ➝ $186.00	High
8/1/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$170.00 ➝ $190.00	High
8/1/2019	UBS Group	Boost Price Target	Neutral	$140.00 ➝ $160.00	High
8/1/2019	Raymond James	Boost Price Target	Outperform	$150.00 ➝ $172.00	High
8/1/2019	BTIG Research	Reiterated Rating	Hold		High
8/1/2019	Canaccord Genuity	Boost Price Target	Buy	$160.00 ➝ $185.00	High
7/31/2019	Piper Jaffray Companies	Boost Price Target	Overweight ➝ Positive	$173.00 ➝ $182.00	High
7/15/2019	Piper Jaffray Companies	Set Price Target	Buy	$173.00	High
6/6/2019	Northland Securities	Reiterated Rating	Hold	$125.00	High
5/2/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$167.00 ➝ $172.00	High
5/2/2019	Raymond James	Lower Price Target	Outperform ➝ Outperform	$160.00 ➝ $150.00	High
5/1/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$173.00	High
4/30/2019	UBS Group	Lower Price Target	Neutral ➝ Neutral	$150.00 ➝ $140.00	High
2/25/2019	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$135.00 ➝ $160.00	Low
2/22/2019	Cowen	Boost Price Target	Outperform	$150.00 ➝ $175.00	High
2/22/2019	Canaccord Genuity	Boost Price Target	Buy	$140.00 ➝ $160.00	High
1/9/2019	Piper Jaffray Companies	Boost Price Target	Average ➝ Overweight	$165.00	High
1/8/2019	UBS Group	Boost Price Target	Neutral ➝ Neutral	$135.00 ➝ $140.00	Medium
1/2/2019	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$150.00 ➝ $135.00	High
12/6/2018	Oppenheimer	Set Price Target	Buy	$150.00	Medium
11/27/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$135.00	Medium
11/21/2018	Oppenheimer	Reiterated Rating	Buy		Medium
11/7/2018	Jefferies Financial Group	Boost Price Target	Buy	$148.00	Low
11/7/2018	Stephens	Boost Price Target	Overweight	$170.00 ➝ $160.00	Low
11/7/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$157.00	Low
11/7/2018	Oppenheimer	Set Price Target	Buy	$150.00	High
10/23/2018	Raymond James	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $150.00	Low
10/19/2018	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$125.00	High
10/11/2018	Morgan Stanley	Boost Price Target	Equal Weight	$130.00 ➝ $150.00	High
9/12/2018	Northland Securities	Upgrade	Under Perform ➝ Market Perform		High
8/23/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Positive	$140.00 ➝ $160.00	Low
8/23/2018	Stephens	Boost Price Target	Overweight ➝ Overweight	$135.00 ➝ $160.00	Low
8/23/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$125.00 ➝ $150.00	Low
8/15/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$127.00 ➝ $145.00	High
8/6/2018	Berenberg Bank	Upgrade	Hold ➝ Buy	$140.00	Low
8/3/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $130.00	Low
8/2/2018	Stephens	Reiterated Rating	Buy	$135.00	Low
8/2/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$106.00 ➝ $127.00	High
8/2/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $125.00	High
8/2/2018	Cowen	Boost Price Target	Outperform	$110.00 ➝ $120.00	High
8/2/2018	BMO Capital Markets	Boost Price Target	Outperformer ➝ Outperform	$112.00 ➝ $125.00	High
8/2/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight	$140.00	High
8/2/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$115.00 ➝ $125.00	High
8/2/2018	Oppenheimer	Set Price Target	Buy	$85.00 ➝ $125.00	High
8/2/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$150.00	High
7/10/2018	BMO Capital Markets	Boost Price Target	Outperform	$112.00	Low
7/2/2018	Raymond James	Upgrade	Market Perform ➝ Outperform		Medium
6/28/2018	Canaccord Genuity	Boost Price Target	Buy	$85.00 ➝ $105.00	Medium
6/12/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$116.00	Low
6/8/2018	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$80.00 ➝ $115.00	Medium
5/11/2018	Bank of America	Initiated Coverage	Buy ➝ Buy	$100.00	Medium
5/4/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $70.00	N/A
5/3/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$81.00 ➝ $85.00	High
5/3/2018	Oppenheimer	Boost Price Target	Outperform	$80.00 ➝ $85.00	High
5/3/2018	BMO Capital Markets	Boost Price Target	Outperformer ➝ Outperformer	$78.00 ➝ $86.00	High
5/3/2018	BTIG Research	Reiterated Rating	Hold		High
4/9/2018	Stephens	Reiterated Rating	Buy	$78.00	Medium
4/4/2018	The Goldman Sachs Group	Initiated Coverage	Sell ➝ Sell	$74.69 ➝ $57.00	High
4/3/2018	Guggenheim	Initiated Coverage	Neutral ➝ Neutral		High
3/29/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Positive	$71.00 ➝ $80.00	Medium
3/29/2018	BMO Capital Markets	Upgrade	Outperform	$78.00	Medium
3/29/2018	Oppenheimer	Set Price Target	Buy	$67.00 ➝ $80.00	Medium
3/29/2018	Piper Jaffray Companies	Set Price Target	Buy	$80.00	Medium
3/23/2018	Piper Jaffray Companies	Set Price Target	Buy	$78.00	High
3/23/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$58.00	High
3/12/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Low
3/4/2018	Northcoast Research	Reiterated Rating	Buy		High
2/28/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $71.00	High
2/28/2018	Oppenheimer	Set Price Target	Buy	$67.00	Medium
2/26/2018	Piper Jaffray Companies	Set Price Target	Buy	$60.00	Low
2/12/2018	Oppenheimer	Set Price Target	Buy	$72.00 ➝ $67.00	Low
1/16/2018	Northland Securities	Reiterated Rating	Sell	$40.00	Low
1/8/2018	Barclays	Reiterated Rating	Hold	$60.00	High
1/4/2018	Northland Securities	Downgrade	Market Perform ➝ Under Perform	$85.00	Low
12/22/2017	Jefferies Financial Group	Boost Price Target	Top Pick ➝ Buy	$58.00 ➝ $70.00	Low
12/12/2017	BMO Capital Markets	Boost Price Target	Outperform	$74.00	Medium
11/3/2017	Morgan Stanley	Lower Price Target	Neutral	$72.00 ➝ $52.00	N/A
11/2/2017	Barclays	Lower Price Target	Equal Weight	$60.00 ➝ $57.00	N/A
11/2/2017	Northland Securities	Reiterated Rating	Hold	$50.00	N/A
10/4/2017	Wedbush	Reiterated Rating	Buy	$76.00	Low
9/29/2017	SVB Leerink	Reiterated Rating	Buy	$85.00 ➝ $57.00	High
9/29/2017	Raymond James	Downgrade	Outperform ➝ Mkt Perform		High
9/28/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$87.00	High
9/28/2017	Stephens	Reiterated Rating	Buy	$83.00 ➝ $70.00	High
9/28/2017	Barclays	Reiterated Rating	Equal Weight	$76.00 ➝ $60.00	High
9/28/2017	Oppenheimer	Lower Price Target	Outperform	$92.00 ➝ $85.00	High
9/28/2017	Robert W. Baird	Lower Price Target	Neutral ➝ Neutral	$79.00 ➝ $58.00	High
9/28/2017	Northland Securities	Downgrade	Outperform ➝ Market Perform	$85.00 ➝ $60.00	High
9/28/2017	Cowen	Lower Price Target	Outperform	$90.00 ➝ $64.00	High
9/28/2017	BMO Capital Markets	Reiterated Rating	Outperform	$90.00 ➝ $62.00	High
9/28/2017	Canaccord Genuity	Reiterated Rating	Buy	$90.00 ➝ $69.00	High
9/28/2017	Raymond James	Reiterated Rating	Outperform ➝ Market Perform	$76.00 ➝ $49.50	High
9/28/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$85.00 ➝ $76.00	High
9/28/2017	Jefferies Financial Group	Reiterated Rating	Buy	$91.00	High
9/28/2017	Citigroup	Downgrade	Outperform ➝ Market Perform		High
9/28/2017	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$93.00 ➝ $71.00	High
9/26/2017	Northland Securities	Initiated Coverage	Outperform ➝ Outperform	$85.00	Low
9/15/2017	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$76.00	Medium
9/10/2017	Robert W. Baird	Reiterated Rating	Hold	$79.00	High
9/8/2017	BMO Capital Markets	Reiterated Rating	Buy	$90.00	High
9/8/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$87.00	Low
8/22/2017	Canaccord Genuity	Reiterated Rating	Buy	$90.00	Low
8/16/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$87.00 ➝ $78.00	Medium
8/8/2017	BMO Capital Markets	Reiterated Rating	Outperform	$105.00 ➝ $90.00	Low
8/2/2017	BMO Capital Markets	Reiterated Rating	Outperform	$105.00 ➝ $90.00	Low
8/2/2017	Stephens	Reiterated Rating	Overweight	$95.00 ➝ $83.00	High
8/2/2017	Oppenheimer	Set Price Target	Buy	$98.00 ➝ $92.00	High
7/14/2017	Cowen	Reiterated Rating	Buy	$90.00	Medium
7/13/2017	BMO Capital Markets	Reiterated Rating	Buy	$105.00	Medium
7/12/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$78.00	Low
6/7/2017	Canaccord Genuity	Reiterated Rating	Buy	$90.00	Low
5/22/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$78.00	Medium
5/9/2017	Jefferies Financial Group	Lower Price Target	Buy	$91.00	Low
5/7/2017	B. Riley	Reiterated Rating	Buy	$95.00	High
5/3/2017	Oppenheimer	Set Price Target	Buy	$98.00	High
5/3/2017	Canaccord Genuity	Lower Price Target	Buy ➝ Buy	$95.00 ➝ $90.00	High
5/3/2017	BTIG Research	Downgrade	Buy ➝ Neutral		High
5/2/2017	B. Riley	Reiterated Rating	Buy	$95.00	High
4/27/2017	B. Riley	Reiterated Rating	Buy	$95.00	High
4/27/2017	William Blair	Reiterated Rating	Outperform		Low
4/18/2017	Cowen	Reiterated Rating	Outperform	$90.00	Low
4/13/2017	Oppenheimer	Reiterated Rating	Buy		Low
4/4/2017	Royal Bank of Canada	Reiterated Rating	Outperform	$87.00	Medium
3/22/2017	Oppenheimer	Reiterated Rating	Buy		Low
3/6/2017	B. Riley	Reiterated Rating	Buy	$95.00	N/A
3/1/2017	B. Riley	Reiterated Rating	Buy	$95.00	N/A
3/1/2017	Northcoast Research	Reiterated Rating	Buy		N/A
3/1/2017	Oppenheimer	Set Price Target	Buy	$98.00	N/A
3/1/2017	Jefferies Financial Group	Boost Price Target	Buy	$80.00 ➝ $91.00	N/A
2/18/2017	B. Riley	Reiterated Rating	Buy	$94.00	N/A
2/16/2017	Robert W. Baird	Reiterated Rating	Neutral	$79.00	N/A
2/13/2017	B. Riley	Reiterated Rating	Buy	$94.00	N/A
2/10/2017	Canaccord Genuity	Reiterated Rating	Buy	$95.00	N/A
1/23/2017	Canaccord Genuity	Set Price Target	Buy	$95.00	N/A
1/13/2017	Oppenheimer	Reiterated Rating	Buy	$98.00	N/A
1/13/2017	BTIG Research	Reiterated Rating	Buy	$92.00	N/A
1/11/2017	Wedbush	Reiterated Rating	Outperform	$85.00	N/A
1/10/2017	Canaccord Genuity	Reiterated Rating	Buy		N/A
1/3/2017	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$87.00 ➝ $66.00	N/A
12/21/2016	Canaccord Genuity	Reiterated Rating	Buy	$70.00	N/A
12/20/2016	B. Riley	Upgrade	Buy	$84.00	N/A
12/19/2016	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$84.00	N/A
12/19/2016	UBS Group	Upgrade	Market Perform ➝ Outperform		N/A
12/15/2016	B. Riley	Upgrade	Neutral ➝ Buy	$84.00	N/A
11/14/2016	Canaccord Genuity	Set Price Target	Buy	$70.00	N/A
11/7/2016	B. Riley	Reiterated Rating	Neutral	$84.00	N/A
11/3/2016	SVB Leerink	Reiterated Rating	Outperform	$115.00 ➝ $100.00	N/A
11/2/2016	B. Riley	Reiterated Rating	Neutral	$84.00	N/A
11/2/2016	Oppenheimer	Set Price Target	Hold	$84.00	N/A
11/2/2016	Canaccord Genuity	Lower Price Target	Buy	$100.00 ➝ $70.00	N/A
11/2/2016	Wedbush	Reiterated Rating	Outperform	$100.00 ➝ $112.00	N/A
10/31/2016	BTIG Research	Upgrade	Neutral ➝ Buy	$92.00	N/A
10/2/2016	B. Riley	Initiated Coverage	Neutral	$97.00	N/A
9/26/2016	B. Riley	Initiated Coverage	Neutral	$97.00	N/A
9/16/2016	BMO Capital Markets	Initiated Coverage	Outperform	$112.00	N/A
9/16/2016	Desjardins	Upgrade	Hold ➝ Buy		N/A
9/14/2016	BTIG Research	Downgrade	Buy ➝ Neutral	$92.00	N/A
8/4/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$93.00 ➝ $100.00	N/A
8/4/2016	BTIG Research	Reiterated Rating	Buy	$92.00	N/A
8/3/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$100.00	N/A
8/3/2016	Jefferies Financial Group	Reiterated Rating	Buy	$98.00	N/A
8/3/2016	Benchmark	Lower Price Target	Buy	$106.00 ➝ $86.00	N/A
7/22/2016	Jefferies Financial Group	Reiterated Rating	Positive	$98.00	N/A
7/20/2016	SVB Leerink	Reiterated Rating	Outperform	$90.00	N/A
7/19/2016	BTIG Research	Reiterated Rating	Buy	$92.00	N/A
7/15/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$93.00	N/A
7/15/2016	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$90.00 ➝ $98.00	N/A
7/15/2016	Jefferies Financial Group	Reiterated Rating	Buy	$90.00 ➝ $98.00	N/A
7/13/2016	Canaccord Genuity	Reiterated Rating	Buy	$95.00	N/A

(Data available from 6/23/2016 forward)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $431.72

$423.26

$433.10

50 Day Range

MA: $380.66

$323.96

$431.72

52 Week Range

Now: $431.72

$305.63

$456.23

Volume

585,845 shs

Average Volume

819,795 shs

Market Capitalization

$41.75 billion

P/E Ratio

84.65

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of DexCom?

The following equities research analysts have issued research reports on DexCom in the last year: Atlantic Securities, Bank of America Co., Barclays PLC, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Stifel Nicolaus, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for DXCM.

What is the current price target for DexCom?

16 Wall Street analysts have set twelve-month price targets for DexCom in the last year. Their average twelve-month price target is $461.19, suggesting a possible upside of 7.9%. Barclays PLC has the highest price target set, predicting DXCM will reach $500.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $380.00 for DexCom in the next year.
View the latest price targets for DXCM.

What is the current consensus analyst rating for DexCom?

DexCom currently has 2 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXCM will outperform the market and that investors should add to their positions of DexCom.
View the latest ratings for DXCM.

What other companies compete with DexCom?

Other companies that are similar to DexCom include Abbott Laboratories, Medtronic, Intuitive Surgical, Stryker, Becton, Dickinson and, Edwards Lifesciences, Boston Scientific, IDEXX Laboratories, Baxter International, ResMed, Teleflex, Insulet, STERIS, Hologic and Abiomed.

How do I contact DexCom's investor relations team?

DexCom's physical mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company's listed phone number is 858-200-0200 and its investor relations email address is [email protected] The official website for DexCom is www.dexcom.com.